Kendall Capital Management Makes New $422,000 Investment in Pfizer Inc. $PFE

Key Points

• Kendall Capital Management has made a new investment of **$422,000** in Pfizer Inc. by purchasing **17,400 shares** during the second quarter.
• Pfizer's recent quarterly earnings report showed an **earnings per share (EPS)** of **$0.78**, exceeding analysts' expectations of **$0.58**, along with a **10.3% year-over-year revenue increase**.
• Several brokerages have recently adjusted their price targets for Pfizer, with the consensus rating currently at **"Hold"** and an average target price of **$28.12**.

Kendall Capital Management bought a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 17,400 shares of the biopharmaceutical company's stock, valued at approximately $422,000.

Several other hedge funds also recently added to or reduced their stakes in PFE. GKV Capital Management Co. Inc. bought a new stake in Pfizer in the first quarter valued at about $27,000. Bayforest Capital Ltd purchased a new position in shares of Pfizer during the 1st quarter valued at $28,000. North Capital Inc. acquired a new position in Pfizer during the 1st quarter worth $28,000. WPG Advisers LLC acquired a new position in shares of Pfizer during the first quarter valued at about $35,000. Finally, Horizon Financial Services LLC bought a new stake in Pfizer in the first quarter valued at about $35,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Price Performance

Shares of NYSE:PFE opened at $23.75 on Friday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43. The business has a 50-day simple moving average of $24.55 and a two-hundred day simple moving average of $24.13. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The firm has a market cap of $135.03 billion, a price-to-earnings ratio of 12.63, a price-to-earnings-growth ratio of 0.77 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the previous year, the company posted $0.60 EPS. The firm's revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently commented on PFE. Citigroup raised their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Bank of America increased their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Wall Street Zen downgraded shares of Pfizer from a "buy" rating to a "hold" rating in a report on Sunday. Finally, Morgan Stanley increased their target price on shares of Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.